Chen et al. found that metformin prevented intestinal barrier dysfunction in colitis, attenuated the loss of tight junction proteins, and reduced bacterial translocation and levels of the pro-inflammatory factors IL-6 (interleukin-6), TNF-α (tumor necrosis factor), and IL-1β (interleukin-1β) [38]. Here, IL6 is linked to colitis.